Fletcher CE., Deng L., Orafidiya F., Yuan W., Lorentzen MPGS., Cyran OW., Varela-Carver A., Constantin TA., Leach DA., Dobbs FM., Figueiredo I., Gurel B., Parkes E., Bogdan D., Pereira RR., Zhao SG., Neeb A., Issa F., Hester J., Kudo H., Liu Y., Philippou Y., Bristow R., Knudsen K., Bryant RJ., Feng FY., Reed SH., Mills IG., de Bono J., Bevan CL.

miR-346 was identified as an activator of Androgen Receptor (AR) signalling that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). We sought to delineate the impact of miR-346 on DNA damage, and its potential as a therapeutic agent.

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

DOI

Type

Journal

Publication Date

Volume

Pages